Interim analysis of survival in a prospective multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test

摘要

BackgroundA 31-gene expression profile (GEP) test that provides risk classification of cutaneous melanoma (CM) patients has been validated in several retrospective studies. The objective of the reported study was a prospective evaluation of the GEP performance in patients enrolled in two clinical registries.